One of the viral exanthems that primarily affects children, erythema infectiosum, which is often called as the fifth disease, is characterized by a typical rash and slight fever. At our company, we are dedicated to advancing the development of vaccines and therapies through cutting-edge research and collaboration with industry partners.
Overview of Erythema Infectiosum
Erythema Infectiosum, or fifth disease, is the result of a parvovirus infection caused by the B19 Parvovirus and is one of the most prevalent viral rashes in children. The condition usually manifests itself with a ‘slapped cheek' and a reticular rash on the limbs. The condition is mostly self-limiting and does not require any therapeutic interventions for recovery. That said, the condition has the potential of also causing aplastic crisis in patients suffering from chronic anemia or hydrops fetalis in a developing fetus.
Fig.1 Analysis of data evaluating the spread of 5th disease. (Qadir M. I., et al., 2019)
Vaccine Development for Erythema Infectiosum
Erythema infectiosum is problematic; however, approved vaccines intended to prevent the spreading of parvovirus infection B19 are still unavailable. On the other hand, a probe of this kind has commenced, and several possibilities are being evaluated:
Live Attenuated Vaccines
These vaccines use a modified form of the virus to stimulate an immune reaction without causing the infection, birthing an eye for development of a live attenuated vaccine. However, it should be emphasized that the safety of immunocompromised people is a priority in this case.
Subunit and Recombinant Vaccines
Such vaccines are based on the use of certain parts of the virus, for instance proteins, in order to induce an immune response. Studies are in progress in order to determine the most immunogenic proteins of parvovirus B19 that may be the targets for such vaccines.
Inactivated Vaccines
Inactivated vaccines utilize previously destroyed viral particles to produce an immune reaction. These immunizations are relatively safer than the rest for high risk groups, but may require absorption in multiple doses for satisfactory security.
DNA Vaccines
DNA vaccines can utilize genetic material derived from the virus to stimulate host's cells to produce viral proteins and consequently evoke an immune reaction. This method is innovative in approach but needs to be validated in clinical trials.
Therapeutics Development for Erythema Infectiosum
The main approach in treating erythema infectiosum has to be management. There are other methods that could be employed such as antipyretics, NSAIDs or antivirals. Antipyretics such as acetaminophen may be taken to alleviate fever while NSAIDs help relieve joint pain and inflammation. With the passing of time, new therapeutic agents that target parvovirus B19 are being evaluated which may include antiviral drugs that prevent viral replication or immunomodulatory medications that activate the body's defense against the infection.
Through our wide array of services, we are known as a top provider of specialized therapies for erythema infectiosum. To understand our services more completely, please click the link down below to learn more.
Our Services
Persistently, we envisage being at the very forefront of efforts to advance an erythema infectiosum vaccine and therapy. Our goal of working collectively to develop vaccine by the infection has been through cutting edge research services, unerring commitment to safety, and function based partnerships.
Disease Models
The model was established through the inoculation of immunosuppressed macaques with simian parvovirus, resulting in enduring anemia resembling the manifestations observed in humans infected with B19 parvovirus.
Preclinical Research
- Pharmacodynamics Study Services
- Pharmacokinetics Study Services
- Drug Safety Evaluation Services
- Customized Research Services
In our robust preclinical studies, the safety and effectiveness of vaccine candidates and therapeutic agents are meticulously assessed. Equipped with cutting-edge technologies, our advanced laboratories facilitate comprehensive testing procedures. If you are interested in our services, please feel free to contact us.
References
- Qadir, M. I., and M. Asif. "Knowledge about erythema infectiosum among university students." J Hum Virol Retrovirology 7.1 (2019): 16-18.
- Kostolansky, Sean, and James R. Waymack. "Erythema Infectiosum." (2018).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
